Mayne Pharma | MYX - 营业费用



金融业
股票价格
AUD
资产
AUD 1.14B
现金及等价物
AUD 110.07M
销售成本
AUD 43.74M
流动资产
AUD 460.59M
流动负债
AUD 313.94M
债务
AUD 38.82M
EBIT
AUD -16.2M
EBITDA
AUD 20.9M
员工
450
EPS每股收益
AUD -0.15
股本和储备
AUD 454.19M
销售毛利
AUD 86.13M
债务利息支出
AUD 1.2M
贷款资金
AUD 2.66M
市值
AUD 206.73M
净收入
AUD -103.68M
营业费用
AUD 103.54M
营业利润
AUD -3.3M
普通股股本
AUD 81.25M
税前利润
AUD -14.7M
销售收入
AUD 212.07M
销售和管理费用
AUD 54.8M
股票
AUD 74.63M
贸易债权人
AUD 30.25M
应收帐款人
AUD 193.22M


营业费用 更改 日
Ansell USD 880.1M 465.65M 2025-12
Avita Medical AUD 28.02M 1.55M 2025-12
Cochlear AUD 914.9M 454.8M 2025-12
CSL USD 5.7B 2.82B 2025-12
Healius AUD 684.9M 261.2M 2024-12
Integral Diagnostics AUD 219.16M 66.76M 2024-06
Medical Developments International AUD 21.61M 11.59M 2025-12
Nanosonics AUD 93.11M 45.89M 2025-12
Polynovo AUD 68.22M 1.24M 2025-12
Ramsay Health Care AUD 8.8B 83.5M 2025-12
ResMed USD 922.51M 49.28M 2025-12
Sigma Healthcare AUD 1.68B 174.89M 2024-12
Sonic Healthcare AUD 4.23B 2.14B 2024-12
Telix Pharmaceuticals AUD 405.4M 26.29M 2025-12